


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



wherein:

Cy is a group of Formula (2):



an optionally substituted heterocyclic ring, C₃₋₇cycloalkyl or phenyl;

R₁, R₂, R₃, R₄ and R₅ are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R₁, R₂, R₃, R₄ and R₅ is halogen, trifluoromethyl or nitrile;

R₆ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, amino or hydroxy;

R₇ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, optionally substituted amino or hydroxy;

R₈ is hydrogen, methyl or ethyl;

R₉ is optionally substituted straight-chained or branched C₁₋₆alkyl, optionally substituted straight-chained or branched C₂₋₆alkenyl, optionally substituted straight-chained or branched C₂₋₆alkynyl, C₃₋₇cycloalkyl or optionally substituted phenyl;


R₂₀ is hydrogen or straight-chained or branched C₁₋₃alkyl or R₉ and R₂₀ may together form C₃₋₇cycloalkyl;

R₁₀ is hydrogen or straight-chained or branched C₁₋₃alkyl;

R₁₁ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, -CO-N(R₁₄)R₁₅, carboxyl or an optionally substituted heterocyclic ring;

R₁₂ is hydroxy or -OR₁₆;

R₁₃ is hydrogen, straight-chained or branched C₁₋₆alkyl, straight-chained or branched C₂₋₆alkenyl, straight-chained or branched C₂₋₆alkynyl or a group of Formula (3):



R₁₄ and R₁₅, which may be the same or different, are hydrogen, optionally substituted straight-chained or branched C₁₋₄alkyl, C₃₋₇cycloalkyl, straight-chained or branched C₁₋₄alkyloxy, straight-chained or branched C₁₋₄alkylsulfonyl or a heterocyclic ring, or R₁₄ and R₁₅, as -N(R₁₄)R₁₅, form optionally substituted 3- to 7-membered cyclic amine;

R₁₆ is straight-chained C₁₋₄alkyl;

R₁₇ is hydrogen or methyl;

R₁₈ and R₁₉ together form cycloalkyl or C₃₋₇cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

provided that

when Cy is 3-indolyl,

- (i) R₁₁ is an optionally substituted heterocyclic ring; or
- (ii) R₆ is hydrogen, R₇ is amino, R₈ is methyl, R₉ is isopropyl, R₂₀ is hydrogen, R₁₀ is methyl, R₁₁ is carbamoyl, R₁₂

is hydroxy, R₁₃ is tert-butyl, X is carbonyl and Y is carbonyl,
and

~~when Cy is cyclohexyl or phenyl, R₁₁ is an optionally
substituted heterocyclic ring;~~
or a hydrate or pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2);
or a hydrate or pharmaceutically acceptable salt thereof.

3. (Original) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which
at least one of R₁, R₂, R₃, R₄ and R₅ is halogen and the others
are hydrogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

4. (Original) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which R₃
is halogen or R₂ and R₃ are the same kind of halogen;
or a hydrate or pharmaceutically acceptable salt thereof.

5. (Original) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which R₃
is halogen and R₁, R₂, R₄ and R₅ are hydrogen, or R₂ and R₃ are
the same kind of halogen and R₁, R₄ and R₅ are hydrogen;
or a hydrate or pharmaceutically acceptable salt thereof.

6. (Original) The compound according to claim 1,
wherein Cy in Formula (1) is a group of Formula (2) in which
at least one of R₁, R₂, R₃, R₄ and R₅ is trifluoromethyl and the
others are hydrogen, halogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

7. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R₁, R₂, R₃, R₄ and R₅ is nitrile and the others are hydrogen, halogen or hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

8. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R₃ is trifluoromethyl; or a hydrate or pharmaceutically acceptable salt thereof.

9. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R₃ is nitrile; or a hydrate or pharmaceutically acceptable salt thereof.

10. (Currently Amended) The compound according to claim 1,

wherein Cy in Formula (1) is an optionally substituted heterocyclic ring provided that when Cy is 3-indolyl,

(i) ~~R₁₁ is an optionally substituted heterocyclic ring; or~~
~~(ii)~~ R₆ is hydrogen, R₇ is amino, R₈ is methyl, R₉ is isopropyl, R₂₀ is hydrogen, R₁₀ is methyl, R₁₁ is carbamoyl, R₁₂ is hydroxy, R₁₃ is tert-butyl, X is carbonyl and Y is carbonyl; or a hydrate or pharmaceutically acceptable salt thereof.

Claims 11-12. (Canceled)

13. (Previously Presented) The compound according to claim 1, wherein R₆ in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

14. (Previously Presented) The compound according to claim 1, wherein R₇ in Formula (1) is hydrogen or optionally substituted amino; or a hydrate or pharmaceutically acceptable salt thereof.

15. (Previously Presented) The compound according to claim 1, wherein R₈ in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

16. (Previously Presented) The compound according to claim 1, wherein R₉ in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl; or a hydrate or pharmaceutically acceptable salt thereof.

17. (Previously Presented) The compound according to claim 1, wherein R₂₀ in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

18. (Previously Presented) The compound according to claim 1, wherein R₁₀ in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

19. (Currently Amended) The compound according to claim 1, wherein R₁₁ in Formula (1) is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tertbutylcarbamoyl, ~~2-pyridylcarbamoyl~~, methoxycarbamoyl, ~~2-thiazolyl~~, ~~1,3,4-oxadiazol-2-yl~~, ~~1,2,4-~~

~~oxadiazol-5-yl, 1,3,4-triazol-2-yl, 6-methyl-4-pyrimidinon-2-yl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, 1-morpholinylcarbonyl, 4-carboxymethyl-1-piperazinecarbonyl, 4-ethoxycarbonylmethyl-1-piperazinecarbonyl or 4-methylsulfonyl-1-piperazinecarbonyl;~~
or a hydrate or pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound according to claim 1, wherein R₁₂ in Formula (1) is hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

21. (Previously Presented) The compound according to claim 1, wherein R₁₃ in Formula (1) is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl; or a hydrate or pharmaceutically acceptable salt thereof.

22. (Currently Amended) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of R₁, R₂, R₃, R₄ and R₅ is halogen and the others are hydrogen or hydroxy;
R₆ is hydrogen or methyl;
R₇ is hydrogen or optionally substituted amino;
R₈ is hydrogen or methyl;
R₉ is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;
R₂₀ is hydrogen;
R₁₀ is hydrogen or methyl;
R₁₁ is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl,

cyclopropylcarbamoyl, tert-butylcarbamoyl, 2-pyridylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl, 1-morpholinylcarbonyl, 4-carboxymethyl-1-piperazinecarbonyl, 4-ethoxycarbonylmethyl-1-piperazinecarbonyl, 4-methylsulfonyl-1-piperazinecarbonyl, 2-thiazolyl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-triazol-2-yl or 6-methyl-4-pyrimidinon-2-yl;

R₁₂ is hydroxy;

R₁₃ is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;

or a hydrate or pharmaceutically acceptable salt thereof.

23. (Original) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(3,4-F₂)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-((2-amino-3-(4-fluorophenyl)propanoyl)-N-methylamino)-3-methylbutyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide,

2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH₂, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂SO₂CH₃, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-


Val-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHET, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH₂OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHiPr; or a hydrate or pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Currently Amended) A compound of Formula (4):



wherein


Cy, R₆, R₈, R₉, R₂₀, R₁₀, R₁₂, R₁₃, X and Y are as defined in claim 1;

R_{7'} is hydrogen, straight-chained or branched C₁₋₃alkyl optionally having at least one protected substituent, amino optionally having at least one protected substituent or protected hydroxy; and

R_{11''} is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, -CO-N(R₁₄)R₁₅, wherein R₁₄ and R₁₅ are as defined in claim 1, carboxyl, straight-chained or branched C₁₋₃alkyl having a protected amino ~~or an optionally substituted heterocyclic ring;~~

or a hydrate or pharmaceutically acceptable salt thereof.

29. (Currently Amended) A compound of Formula (5):



wherein:


Cy, R₆, R₈, R₉, R₂₀, R₁₀, R₁₂, R₁₃, X and Y are as defined in claim 1;

R_{7''} is hydrogen, straight-chained or branched C₁₋₃alkyl optionally having at least one optionally protected substituent, amino optionally having at least one optionally protected substituent or optionally protected hydroxy; and

R_{11'} is hydrogen, straight-chained or branched C₁₋₃alkyl optionally having at least one protected substituent, -CO-N(R₁₄)R₁₅ wherein R₁₄ and R₁₅ are as defined in claim 1, carboxyl ~~or an optionally substituted heterocyclic ring;~~

or a hydrate or pharmaceutically acceptable salt thereof.

30. (Previously Presented) A compound of Formula (6):



wherein:

R₈ is hydrogen, optionally-substituted straight-chained or branched C₁₋₃ alkyl, optionally substituted amino, or hydroxy;


R₉, is optionally-substituted straight-chained or branched C₁₋₆ alkyl, optionally substituted straight-chained or branched C₂₋₆ alkenyl, optionally substituted straight-chained or branched C₂₋₆ alkynyl, C₃₋₇ cycloalkyl or optionally substituted phenyl;

R₂₀ is hydrogen or straight-chained or branched C₁₋₃ alkyl;

R₁₀ is hydrogen or straight-chain or branched C₁₋₃ alkyl;

R₁₂ is hydroxy or ORO₁₆;

R₁₃ is hydrogen, straight-chained or branched C₂₋₆ alkenyl, straight-chained or branched C₂₋₆ alkynyl or a group of Formula (3)



Wherein R₁₇ is hydrogen or methyl;

R₁₈ and R₁₉ together form cycloalkenyl or C₃₋₇ cycloalkenyl; and

Y is carbonyl or methylene;

P₁ is hydrogen or a protecting group of amine; and

R₁₁''' is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, -CO-N(R₁₄)R₁₅ wherein R₁₄ and R₁₅, which may be the same or different, are hydrogen, optionally substituted straight-chained or branched C₁₋₄ alkyl, C₃₋₇ cycloalkyl, straight-chained or branched C₁₋₄ alkoxy, straight-chained or branched C₁-alkylsulfonyl or a heterocyclic ring, or R₁₄ and R₁₅, as -N(R₁₄)R₁₅, form optionally substituted 3-7 cyclic amine, carboxyl, straight-chained or branched C₁₋₃alkyl having protected amino or an optionally substituted heterocyclic ring;
or a hydrate or pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)